Forte Biosciences Inc expected to post a loss of 32 cents a share - Earnings Preview

Forte Biosciences

03/09/2021 13:41

* Forte Biosciences Inc  FBRX.OQ   FBRX.O  is expected to show a
no change in quarterly revenue when it reports results on
September 7. 
​* Refinitiv's mean analyst estimate for Forte Biosciences Inc
is for a loss of 32 cents per share. For the same quarter last
year, the company reported a loss of 45 cents per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell." 
* The mean earnings estimate of analysts had fallen by
about 2.3% in the last three months. ​
* Wall Street's median 12-month price target for Forte
Biosciences Inc is $4​, about 614.7% below​ its last closing
price of $28.59. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -0.44       -0.43      -0.43     Met     0.6
 Mar. 31 2021  -0.45       -0.52      -0.36     Beat    31.4
 Dec. 31 2020              -0.57      -0.37     Beat    35.5​
 Sep. 30 2020  -0.54       -0.54      -0.45     Beat    16.7
 Jun.          -0.19​      -0.19      -9.52     Missed  -4,910
 30​ 2020​                                              .5​
 Mar. 31 2020              -6.60      -6.45     Beat    2.3​
 Dec. 31 2019  -8.58       -8.55      -7.50     Beat    12.3
 Sep. 30 2019  -10.33      -10.49     -11.70    Missed  -11.5
 This summary was machine generated September 3 at 12:41 GMT. 
All figures in US dollars unless otherwise stated